Market Summary
USD50.57-0.76
Market Closed-1.48%
BPMC Stock Price
BPMC RSI Chart
BPMC Valuation
BPMC Price/Sales (Trailing)
BPMC Profitability
BPMC Fundamentals
BPMC Revenue
BPMC Earnings
Price Action
52 Week Range
37.8271.32
(Low)(High)
Last 7 days
-2.6%
Last 30 days
0.0%
Last 90 days
-21.1%
Trailing 12 Months
-28.0%
BPMC Financial Health
BPMC Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for BPMC
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-25 | Albers Jeffrey W. | sold | -501,600 | 50.16 | -10,000 | - |
2023-08-25 | Albers Jeffrey W. | acquired | 18,700 | 1.87 | 10,000 | - |
2023-08-24 | Albers Jeffrey W. | sold | -743,550 | 49.57 | -15,000 | - |
2023-08-24 | Albers Jeffrey W. | acquired | 28,050 | 1.87 | 15,000 | - |
2023-06-21 | Borisy Alexis | acquired | - | - | 2,600 | - |
2023-06-21 | Seely Lynn | acquired | - | - | 2,600 | - |
2023-06-21 | Dable Habib J | acquired | - | - | 2,600 | - |
2023-06-21 | Albers Jeffrey W. | acquired | - | - | 2,600 | - |
2023-06-21 | Tsai John | acquired | - | - | 2,600 | - |
2023-06-21 | Beckman Daniella | acquired | - | - | 2,600 | - |
Which funds bought or sold BPMC recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | 109 | 379 | -% |
2023-08-29 | EFG Asset Management (Americas) Corp. | reduced | -18.11 | 45,447 | 347,600 | 0.08% |
2023-08-23 | WOLVERINE TRADING, LLC | sold off | -100 | -201,000 | - | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 10.21 | 579,615 | 1,636,880 | 0.02% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.38 | 1,249,420 | 4,614,360 | 0.01% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 5.25 | 53,784 | 165,902 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | reduced | -19.29 | 147,000 | 1,246,000 | 0.01% |
2023-08-16 | Neo Ivy Capital Management | new | - | 222,000 | 222,000 | 0.12% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -3.12 | 2,921,470 | 11,017,500 | -% |
2023-08-16 | TD Capital Management LLC | unchanged | - | 2,367 | 8,216 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Blueprint Medicines
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | price t rowe associates inc /md/ | 7.2% | 4,299,290 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.65% | 5,774,456 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 8.36% | 5,003,428 | SC 13G/A | |
| Jan 26, 2023 | blackrock inc. | 10.5% | 6,274,522 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 10.5% | 6,274,522 | SC 13G/A | |
| Nov 09, 2022 | blackrock inc. | 10.0% | 5,992,603 | SC 13G/A | |
| May 10, 2022 | fmr llc | - | 0 | SC 13G | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 7.7% | 4,550,539 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 9.41% | 5,533,771 | SC 13G/A |
Recent SEC filings of Blueprint Medicines
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Aug 28, 2023 | 4 | Insider Trading | |
| Aug 25, 2023 | 8-K | Current Report | |
| Aug 24, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 02, 2023 | 8-K | Current Report | |
| Aug 02, 2023 | 10-Q | Quarterly Report | |
| Jun 30, 2023 | 8-K | Current Report | |
| Jun 27, 2023 | 8-K | Current Report | |
| Jun 23, 2023 | 4 | Insider Trading | |
| Jun 23, 2023 | 4 | Insider Trading | |
| Jun 23, 2023 | 4 | Insider Trading |
Peers (Alternatives to Blueprint Medicines)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABBV | 271.4B | 56.0B | 2.30% | 9.45% | 31.25 | 4.84 | -2.31% | -31.27% |
BGNE | 265.4B | 1.8B | -1.67% | 25.43% | -153.19 | 146.56 | 69.45% | 14.65% |
VRTX | 90.8B | 9.5B | 0.45% | 22.78% | 26.99 | 9.56 | 13.83% | 5.33% |
REGN | 89.0B | 12.7B | -1.51% | 18.09% | 20.7 | 7.02 | -10.94% | -24.40% |
ALNY | 21.9B | 1.2B | -7.00% | -17.21% | -20.61 | 17.72 | 39.94% | -8.44% |
SRPT | 11.0B | 1.0B | 3.70% | 3.57% | -12.12 | 10.97 | 20.15% | -79.16% |
UTHR | 10.5B | 2.1B | -3.12% | 8.08% | 12.05 | 4.98 | 18.01% | 38.16% |
| MID-CAP | ||||||||
BPMC | 3.1B | 225.6M | 0.04% | -28.00% | -5.53 | 13.59 | -2.11% | 21.02% |
MDGL | 3.0B | - | -10.01% | 147.80% | -9.03 | - | - | -28.88% |
RARE | 2.6B | 402.9M | -2.14% | -20.15% | -3.59 | 6.42 | 20.50% | -42.46% |
MRTX | 1.9B | 27.2M | -14.18% | -57.07% | -2.57 | 69.63 | - | -14.43% |
| SMALL-CAP | ||||||||
CYTK | 3.1B | - | -2.94% | -39.70% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.3B | 302.9M | -16.58% | -4.84% | 11.23 | 4.28 | 77.72% | 112.02% |
MGNX | 281.2M | 152.5M | -11.67% | 38.41% | 37.75 | 1.84 | 127.84% | 103.41% |
CRBP | 29.9M | - | 1.35% | 3552.08% | -0.65 | - | - | -31.51% |
Blueprint Medicines News
Returns for BPMC
Cumulative Returns on BPMC
8.2%
7-Year Cumulative Returns
-6.2%
5-Year Cumulative Returns
-14.0%
3-Year Cumulative Returns
Risks for BPMC
What is the probability of a big loss on BPMC?
100%
Probability that Blueprint Medicines stock will be more than 20% underwater in next one year
90.8%
Probability that Blueprint Medicines stock will be more than 30% underwater in next one year.
60%
Probability that Blueprint Medicines stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does BPMC drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Blueprint Medicines was unfortunately bought at previous high price.
Drawdowns
Financials for Blueprint Medicines
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 10.3% | 225,615,000 | 204,592,000 | 204,036,000 | 272,276,000 | 230,487,000 | 221,235,000 | 180,080,000 | 333,493,750 | 486,907,500 | 640,321,250 | 793,735,000 | 553,139,667 | 312,544,333 | 71,949,000 | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 427,838,000 | 391,102,000 | 360,605,000 | 322,487,000 | 291,549,000 | 259,095,000 | 229,170,000 |
| S&GA Expenses | 5.3% | 264,509,000 | 251,266,000 | 237,374,000 | 227,554,000 | 219,752,000 | 210,350,000 | 195,293,000 | 183,634,000 | 171,203,000 | 164,091,000 | 157,743,000 | 147,469,000 | 135,741,000 | 115,490,000 | 96,388,000 | 77,766,000 | 64,160,000 | 54,570,000 | 47,928,000 | 42,377,000 | 37,714,000 |
| R&D Expenses | -3.8% | 467,957,000 | 486,360,000 | 477,419,000 | 716,456,000 | 672,894,000 | 624,455,000 | 601,033,000 | 321,560,000 | 311,371,000 | 322,423,000 | 326,860,000 | 338,101,000 | 345,324,000 | 341,346,000 | 331,450,000 | 313,336,000 | 296,445,000 | 267,917,000 | 243,621,000 | 216,718,000 | 191,456,000 |
| EBITDA | 100.0% | - | -584,743,000 | -557,313,000 | -711,406,000 | -687,252,000 | -638,588,000 | -632,219,000 | -400,656,000 | 351,363,000 | 325,969,000 | 328,098,000 | 607,838,000 | -361,429,333 | -329,156,000 | -328,703,000 | -350,997,000 | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -2.86 | -2.73 | -2.61 | -2.98 | -2.89 | -3.51 | -1.20 | 0.72 | 0.51 | 0.41 | 1.10 | -1.16 | -4.57 | -15.34 | -16.38 | - | - | - | - | - |
| Interest Expenses | -19.2% | -27,451,000 | -23,028,000 | -16,767,000 | -7,064,000 | 1,884,000 | 2,090,000 | 2,386,000 | 2,859,000 | 3,480,000 | 4,433,000 | 6,599,000 | 8,653,000 | 11,238,000 | 13,927,000 | 13,732,000 | 21,248,000 | 17,520,000 | 13,258,000 | 10,566,000 | 3,140,000 | 3,144,000 |
| Earnings Before Taxes | 4.2% | -551,530,000 | -575,506,000 | -552,281,000 | -710,724,000 | -695,513,000 | -647,185,000 | -641,084,000 | -410,011,000 | 341,403,000 | 326,180,000 | 314,940,000 | 592,724,000 | -378,773,333 | - | -347,694,000 | -377,100,000 | - | - | -236,642,000 | - | - |
| EBT Margin | 100.0% | - | -2.81 | -2.71 | -2.61 | -3.02 | -2.93 | -3.56 | -1.23 | 0.70 | 0.49 | 0.40 | 1.07 | -1.21 | -4.83 | -16.23 | -17.60 | - | - | - | - | - |
| Net Income | 4.6% | -554,162,000 | -581,078,000 | -557,517,000 | -717,557,000 | -701,635,000 | -650,370,000 | -644,085,000 | -411,067,000 | 340,152,000 | 325,122,000 | 313,882,000 | 333,220,000 | -395,033,000 | -371,240,000 | -347,694,000 | -361,685,000 | -340,133,000 | -267,500,000 | -236,642,000 | -205,347,000 | -170,327,000 |
| Net Income Margin | 100.0% | - | -2.84 | -2.73 | -2.64 | -3.04 | -2.94 | -3.58 | -1.23 | 0.70 | 0.51 | 0.40 | 0.60 | -1.26 | -5.16 | -16.23 | -16.88 | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -502,862,000 | -511,196,000 | -403,682,000 | -366,655,000 | -309,670,000 | -301,742,000 | -311,856,000 | 407,056,000 | 368,778,000 | 383,876,000 | 360,576,000 | -339,630,000 | -320,923,000 | -292,028,000 | -311,249,000 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -9.3% | 1,106 | 1,220 | 1,350 | 1,458 | 1,192 | 1,143 | 1,252 | 1,477 | 1,569 | 1,625 | 1,718 | 1,558 | 817 | 914 | 708 | 738 | 807 | 545 | 594 | 606 | 665 |
| Current Assets | -9.9% | 811 | 900 | 1,047 | 1,228 | 952 | 687 | 554 | 772 | 704 | 938 | 928 | 842 | 568 | 705 | 517 | 514 | 613 | 427 | 500 | 566 | 622 |
| Cash Equivalents | -55.5% | 76.00 | 170 | 120 | 291 | 173 | 37.00 | 215 | 554 | 534 | 698 | 685 | 565 | 289 | 375 | 120 | 89.00 | 82.00 | 79.00 | 73.00 | 79.00 | 118 |
| Inventory | -2.9% | 17.00 | 18.00 | 30.00 | 35.00 | 35.00 | 30.00 | 22.00 | 17.00 | 15.00 | 16.00 | 9.00 | 6.00 | 4.00 | 3.00 | - | - | - | - | - | - | - |
| Net PPE | 9.5% | 37.00 | 34.00 | 33.00 | 33.00 | 33.00 | 31.00 | 31.00 | 31.00 | 32.00 | 33.00 | 34.00 | 35.00 | 37.00 | 38.00 | 38.00 | 38.00 | 34.00 | 31.00 | 30.00 | 30.00 | 30.00 |
| Liabilities | -1.3% | 795 | 806 | 835 | 818 | 445 | 262 | 281 | 230 | 240 | 225 | 248 | 238 | 236 | 231 | 243 | 222 | 214 | 200 | 175 | 117 | - |
| Current Liabilities | -2.1% | 169 | 173 | 183 | 176 | 159 | 137 | 150 | 120 | 125 | 112 | 131 | 110 | 105 | 98.00 | 106 | 94.00 | 82.00 | 65.00 | 60.00 | 56.00 | 50.00 |
| LT Debt, Current | - | - | - | - | - | 6.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| LT Debt, Non Current | - | - | - | - | - | 166 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Shareholder's Equity | -24.9% | 311 | 414 | 515 | 640 | 748 | 882 | 971 | 1,247 | 1,329 | 1,400 | 1,470 | 1,320 | 581 | 683 | 464 | 516 | 593 | 344 | 419 | 489 | 553 |
| Retained Earnings | -6.8% | -2,095 | -1,962 | -1,832 | -1,674 | -1,541 | -1,381 | -1,275 | -956 | -839 | -731 | -631 | -545 | -1,179 | -1,056 | -945 | -878 | -784 | -684 | -597 | -517 | -444 |
| Additional Paid-In Capital | 1.2% | 2,411 | 2,381 | 2,358 | 2,329 | 2,303 | 2,275 | 2,250 | 2,209 | 2,174 | 2,136 | 2,107 | 1,868 | 1,762 | 1,739 | 1,412 | 1,395 | 1,376 | 1,029 | 1,017 | 1,007 | 998 |
| Shares Outstanding | 0.4% | 61.00 | 60.00 | 60.00 | 60.00 | 60.00 | 59.00 | 59.00 | 59.00 | 58.00 | 58.00 | 58.00 | 55.00 | 54.00 | 53.00 | 49.00 | 49.00 | 49.00 | 44.00 | 44.00 | 44.00 | 44.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -2.5% | -504 | -492 | -502 | -394 | -360 | -305 | -298 | -309 | 409 | 371 | 387 | 367 | -327 | -307 | -278 | -300 | -284 | -205 | -175 | -142 | -113 |
| Share Based Compensation | -1.5% | 97.00 | 99.00 | 99.00 | 96.00 | 95.00 | 94.00 | 92.00 | 88.00 | 84.00 | 79.00 | 76.00 | 72.00 | 67.00 | 61.00 | 55.00 | 48.00 | 41.00 | 35.00 | 31.00 | 25.00 | 21.00 |
| Cashflow From Investing | -69.9% | 19.00 | 64.00 | -149 | -443 | -206 | -399 | -225 | 46.00 | -488 | -361 | -434 | -290 | 214 | -45.92 | -16.47 | -27.96 | -85.91 | 147 | -161 | -167 | -191 |
| Cashflow From Financing | - | 766 | - | 562 | 577 | 208 | 45.00 | 51.00 | 253 | 326 | 315 | 618 | 400 | 320 | 649 | 341 | 340 | 335 | 3.00 | 4.00 | 332 | 332 |
BPMC Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues: | ||||
| Revenue | $ 57,570 | $ 36,547 | $ 120,857 | $ 99,278 |
| Cost and operating expenses: | ||||
| Cost of sales | 2,323 | 4,886 | 5,498 | 9,964 |
| Research and development | 110,063 | 128,466 | 222,135 | 231,599 |
| Selling, general and administrative | 71,931 | 58,688 | 142,882 | 115,747 |
| Collaboration loss sharing | 1,234 | 2,145 | 2,530 | 5,410 |
| Total cost and operating expenses | 185,551 | 194,185 | 373,045 | 362,720 |
| Other income (expense): | ||||
| Interest income (expense), net | (3,996) | 427 | (9,815) | 869 |
| Other income (expense), net | (626) | 632 | 359 | 177 |
| Total other income (expense), net | (4,622) | 1,059 | (9,456) | 1,046 |
| Loss before income taxes | (132,603) | (156,579) | (261,644) | (262,396) |
| Income tax expense | 190 | 3,130 | 710 | 3,313 |
| Net loss | (132,793) | (159,709) | (262,354) | (265,709) |
| Other comprehensive loss: | ||||
| Unrealized gains (losses) on available-for-sale investments | 361 | (2,308) | 6,181 | (10,328) |
| Currency translation adjustments | 20 | 170 | 41 | 213 |
| Comprehensive loss | $ (132,412) | $ (161,847) | $ (256,132) | $ (275,824) |
| Net loss per share - basic (in dollars per share) | $ (2.19) | $ (2.68) | ||
| Net loss per share - diluted (in dollars per share) | $ (2.19) | $ (2.68) | $ (4.35) | $ (4.47) |
| Weighted-average number of common shares used in net loss per share - basic (in shares) | 60,516 | 59,617 | ||
| Weighted-average number of common shares used in net loss per share - diluted (in shares) | 60,516 | 59,617 | 60,322 | 59,465 |
| Product revenue, net | ||||
| Revenues: | ||||
| Revenue | $ 39,876 | $ 28,454 | $ 78,945 | $ 52,295 |
| Collaboration and license revenue | ||||
| Revenues: | ||||
| Revenue | $ 17,694 | $ 8,093 | $ 41,912 | $ 46,983 |
BPMC Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 75,527 | $ 119,709 |
| Marketable securities | 647,107 | 825,283 |
| Accounts receivable | 35,147 | 23,525 |
| Unbilled accounts receivable | 3,120 | 13,413 |
| Inventory | 17,016 | 29,697 |
| Prepaid expenses and other current assets | 33,418 | 35,024 |
| Total current assets | 811,335 | 1,046,651 |
| Marketable securities | 113,932 | 133,480 |
| Property and equipment, net | 36,957 | 33,344 |
| Operating lease right-of-use assets, net | 77,529 | 81,854 |
| Restricted cash | 6,352 | 5,195 |
| Equity investment | 27,789 | 27,789 |
| Other assets | 32,551 | 21,589 |
| Total assets | 1,106,445 | 1,349,902 |
| Current liabilities: | ||
| Accounts payable | 6,979 | 2,729 |
| Accrued expenses | 101,162 | 131,123 |
| Current portion of operating lease liabilities | 11,292 | 10,579 |
| Current portion of deferred revenue | 3,328 | 4,667 |
| Current portion of liabilities related to the sale of future royalties and revenues | 28,410 | 17,285 |
| Current portion of term loan | 17,857 | 16,851 |
| Total current liabilities | 169,028 | 183,234 |
| Operating lease liabilities, net of current portion | 87,049 | 92,789 |
| Deferred revenue, net of current portion | 5,000 | 13,624 |
| Liabilities related to the sale of future royalties and revenues, net of current portion | 408,931 | 413,045 |
| Term loan, net of current portion | 122,146 | 122,232 |
| Other long-term liabilities | 3,161 | 10,301 |
| Total liabilities | 795,315 | 835,225 |
| Commitments and Contingencies (Note 15) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding | ||
| Common stock, $0.001 par value; 120,000,000 shares authorized; 60,638,275 and 59,958,919 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 61 | 60 |
| Additional paid-in capital | 2,410,601 | 2,358,018 |
| Accumulated other comprehensive loss | (4,221) | (10,443) |
| Accumulated deficit | (2,095,311) | (1,832,958) |
| Total stockholders' equity | 311,130 | 514,677 |
| Total liabilities and stockholders' equity | $ 1,106,445 | $ 1,349,902 |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.